Nxera Pharma (4565.T) Earnings Analysis
Nxera Pharma (4565.T) next reports earnings on 2026-08-07, consensus EPS -3.5254 JPY. It has beaten estimates in 2/6 recent quarters (33%). Trailing P/E -8.19.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 4565.T next report earnings?
| Next earnings date | 2026-08-07 |
|---|---|
| Consensus EPS estimate | -3.5254 JPY |
| Revenue estimate | 8.48B |
4565.T earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-01 | 19.82 JPY | n/a | n/a | n/a |
| 2026-02-13 | -85.49 JPY | 73.9 JPY | -215.7% | Miss |
| 2025-10-31 | -18.47621 JPY | 22.29 JPY | -182.9% | Miss |
| 2025-08-08 | -26.38046 JPY | 17.83 JPY | -248% | Miss |
| 2025-05-02 | -8.45 JPY | -40.12 JPY | +78.9% | Beat |
| 2024-11-01 | 13.45 JPY | -41.01 JPY | +132.8% | Beat |
| 2024-08-09 | -15.83 JPY | 1.96 JPY | -907.7% | Miss |
Beat rate: 2/6 (33%) over reported quarters with consensus data.
4565.T valuation and analyst view
| Trailing P/E | -8.19 |
|---|---|
| Trailing EPS | -110.24919 JPY |
| Price / book | 1.29 |
| Dividend yield | 0.00% |
| Market cap | 84.48B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Nxera Pharma (4565.T)'s next earnings date?
Nxera Pharma is next scheduled to report on 2026-08-07, with a consensus EPS estimate of -3.5254 JPY and revenue estimate of 8.48B.
Did 4565.T beat earnings last quarter?
Consensus estimate data was not available for 4565.T's 2026-05-01 report.
What is 4565.T's earnings track record?
Over the last 6 reported quarters with consensus data, 4565.T beat estimates 2 times (33%).
What is 4565.T's current P/E ratio and EPS?
4565.T trades at a trailing P/E of -8.19 on trailing EPS of -110.2491850378474 JPY.
What do analysts rate 4565.T?
4565.T has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.